Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Wang



Author of

  • +

    P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P3.01-024 - The Effect of Pemetrexed as First Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangements (ID 1179)

      09:30 - 09:30  |  Author(s): Y. Wang

      • Abstract
      • Slides

      Background:
      The efficacy of pemetrexed-based first-line chemotherapy in ALK-positive NSCLC has been documented in several studies. More data for Chinese population are still needed.

      Methods:
      We retrospectively reviewed the chart of 34 patients with ALK-positive advanced NSCLC. All of them had received pemetrexed as the first-line chemotherapy in our hospital from May 2011 to October 2014. We analyzed the clinical characteristics and treatment outcomes of these patients.The primary end points were response rate and progression-free survival.

      Results:
      The median age was 52 years (range from 34 to 76) and 58.8% (20/34) of the patients were never smokers. All tumors were adenocarcinoma. There were two cases harboring ALK translocation and EGFR mutation. Pemetrexed combined with platinum was administered in the first-line setting and the median treatment cycle was 4.5. The median progression-free survival (PFS) of ALK-positive patients was 8.8 months (95%CI 7.397-10.213). At the time of analysis, 7 with PR (20.6%)，23 with SD (67.6%)，4 with PD (11.8%) and no CR achieved. The objective response rate was 20.6% (7/34)，and the disease control rate was 88.2% (30/34). Common adverse events with pemetrexed were neutropenia (52.9%)，nausea (58.8%)，transaminase elevation (29.4%) and fatigue (9.3%)，mainly in grade 1 or 2.

      Conclusion:
      Pemetrexed is efficient and well tolerated as first-line treatment for ALK-positive NSCLC in Chinese population. Thus, pemetrexed might provide an alternative option for the treatment of ALK-positive lung adenocarcinoma.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.